peptide mapping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
=== United States === The approach in the United States to stop money laundering is usually broken into two areas: preventive (regulatory) measures, and prosecutorial measures. In the United States, whistleblowers can report money laundering activities to the Financial Crimes Enforcement Network (FinCEN) or the Securities and Exchange Commission (SEC) if the case also implicates a security.
The Bain de Soleil brand transitioned from Procter & Gamble (P&G) to Pfizer in August 1995. The product recipes and certain pieces of manufacturing and packaging equipment were relocated from Hatboro, PA (P&G) to Pfizer Consumer Healthcare Group in Parsippany, New Jersey around October 1995. From November 1995 to 1999, the product was manufactured and packaged at the Pfizer CHCG 100 Jefferson Road, Parsippany, NJ site. During this time, the brand saw the largest portfolio enlargement, including self-tanning (sunless) and after-sun products. These products were all formulated at the same Pfizer site at the 400 Webro Road laboratories. Between 1995 and 1999, the following Bain de Soleil products were marketed:
In February 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the US market because a safety clinical trial showed an increased occurrence of cancer. The drug manufacturer, Eisai, voluntarily withdrew the drug.
87Rb, 187Re, 176Lu, 232Th, and 238U have half-lives long enough that their decay is limited over geological time scales; 40K and 235U have shorter half-lives and are hence severely depleted, but are still long-lived enough to remain present in significant amount on Earth. The longest-lived isotope not proven to be primordial is 146Sm, which has a half-life of 9.20×107 years, followed by 244Pu (8.13×107 years) and 92Nb (3.47×107 years). 244Pu was reported to exist in nature as a primordial nuclide in 1971, but this detection could not be confirmed by further studies in 2012 and 2022. Taking into account that all these nuclides must exist for at least 4.58×109 years, 146Sm must survive 50 half-lives (and hence be reduced by 250 ≈ 1×1015), 244Pu must survive 57 (and be reduced by a factor of 257 ≈ 1×1017), and 92Nb must survive 130 (and be reduced by 2130 ≈ 1×1039). Mathematically, considering the likely initial abundances of these nuclides, primordial 146Sm and 244Pu should persist somewhere within the Earth today, even if they are not identifiable in the relatively minor portion of the Earth's crust available to human assays, while 92Nb and all shorter-lived nuclides should not. Nuclides such as 92Nb that were present in the primordial solar nebula but have long since decayed away completely are termed extinct radionuclides if they have no other means of being regenerated. As for 244Pu, calculations suggest that as of 2022, sensitivity limits were about one order of magnitude away from detecting it as a primordial nuclide.
=== Insulin glargine/lixisenatide === Insulin glargine/lixisenatide, marketed under the brand name Soliqua, is a fixed-dose combination medication that combines insulin glargine and lixisenatide for the treatment of diabetes. The most common side effects include hypoglycemia, diarrhea, vomiting, and nausea. Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017. It is currently only marketed by Sanofi as Soliqua.
Sources: en.wikipedia.org
These numbers may be low due to insufficient food intake data. The concentrations of nicotine in vegetables are difficult to measure accurately, since they are very low (parts per billion range). The biological function of nicotine in the tobacco plant is as an antiherbivore neurotoxin. Some species have evolved resistance to nicotine, such as Manduca sexta. In the tobacco plant, it is produced in the roots, then transported to the leaves. It has little effect on the plant itself. Grafting the top of a tomato plant to a tobacco root does not harm the tomato plant despite accumulating nicotine in the leaves. Conversely, grafting the top of a tobacco plant to a tomato root does not harm the tobacco plant, despite not receiving nicotine.
The Joint Committee for Traceability in Laboratory Medicine or JCTLM is collaboration between the International Bureau of Weights and Measures (BIPM), the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC), and the International Laboratory Accreditation Cooperation (ILAC). The goal of the JCTLM is to provide a worldwide platform to promote and give guidance on internationally recognized and accepted equivalence of measurements in laboratory medicine and traceability to appropriate measurement standards.
Russell demonstrated that alkaline vents create an abiogenic proton motive force chemiosmotic gradient, ideal for abiogenesis. Their microscopic compartments "provide a natural means of concentrating organic molecules," composed of iron-sulfur minerals such as mackinawite, endowed these mineral cells with the catalytic properties envisaged by Günter Wächtershäuser. This movement of ions across the membrane depends on two factors:
== Further reading == Coluzzi F, Mattia C (July–August 2005). "Oxycodone. Pharmacological profile and clinical data in chronic pain management" (PDF). Minerva Anestesiologica. 71 (7–8): 451–460. PMID 16012419. Archived from the original (PDF) on March 9, 2006.
Climate change in Brazil is causing higher temperatures and longer-lasting heatwaves, changing precipitation patterns, more intense wildfires and heightened fire risk. Brazil's hydropower, agriculture and urban water supplies will be affected. Brazil's rainforests, and the Amazon, are particularly at risk to climate change. At worst, large areas of the Amazon River basin could turn into savannah, with severe consequences for global climate and local livelihoods. Extreme weather events like droughts and flash floods are causing annual losses of around R$13 billion (US$2.6 billion), equivalent to 0.1% of the country's 2022 GDP. Climate impacts could exacerbate poverty. Brazil's greenhouse gas emissions per person are higher than the global average, and Brazil is among the top 10 highest emitting countries. Greenhouse gas emissions by Brazil are over 4% of the annual world total. In 2026 the Brazilian government has launched a National Climate Change Plan which should cut greenhouse gas emissions by 59% - 67% by 2035, and make the country carbon neutral by 2050. Brazil hosted the 2025 United Nations Climate Change Conference, in which it launched the Global carbon market coalition immediately joined by 11 countries including Brazil, China, the European Union, United Kingdom. According to some calculations, a global carbon market can speed up emission reduction seven-fold.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.